Finally, CLK4 inhibition has broader applicability, as splicing abnormalities have been identified in other cancers, including MET gene splicing in lung cancer and exon 7 splicing defects in androgen receptor genes in prostate cancer.[28, 29] Targeting CLK4 presents versatile and impactful opportunities for advancing cancer therapies, as it plays a pivotal role in RNA splicing across various cancer types. This evidence concerns the gene MET and prostate carcinoma.